The Experts below are selected from a list of 321 Experts worldwide ranked by ideXlab platform
Kyle G. Mathews - One of the best experts on this subject based on the ideXlab platform.
-
Sinonasal aspergillosis: Outcome after Topical Treatment in dogs with cribriform plate lysis.
Journal of Veterinary Internal Medicine, 2018Co-Authors: Beatriz Belda, Nicholas Petrovitch, Kyle G. MathewsAbstract:BACKGROUND Cribriform lysis has been considered a contraindication for Topical Treatment of sinonasal aspergillosis (SNA) because of concerns about drug extravasation with resultant neurologic signs or death. OBJECTIVE/HYPOTHESIS To describe dogs with SNA and cribriform plate lysis treated with Topical antifungal medications. Our hypothesis was that the conventional dogma that Topical therapy should be avoided in these cases is incorrect. ANIMALS Nine client-owned dogs with SNA and lysis of the cribriform plate, lysis of the floor of a frontal sinus or both detected by computed tomography (CT). METHODS A retrospective review of medical records was performed. Dogs that met inclusion criteria (ie, SNA confirmed by at least 1 laboratory test, braincase affected on CT, and Topical Treatment applied) were included. Size of lesions, ancillary diagnostic test results, Topical therapy, and adjuvant PO Treatments were recorded. Outcome was determined by phone calls. RESULTS Four dogs were alive at the time of the manuscript submission with follow-up ranging from 188 to 684 days without neurological signs observed. All dogs were discharged without major complication 1-7 days postoperatively. One dog that had presented with a history of seizures experienced seizure activity 2 months after Treatment. CONCLUSIONS AND CLINICAL IMPORTANCE Topical therapy did not result in complications in these dogs in which lytic regions as large as 16 × 22 mm2 were noted. Sinonasal aspergillosis associated lysis of the cribriform plate; lysis of the floor of a frontal sinus or both detected on CT is not necessarily a contraindication to Topical therapy.
-
Sinonasal aspergillosis: Outcome after Topical Treatment in dogs with cribriform plate lysis.
Journal of veterinary internal medicine, 2018Co-Authors: Beatriz Belda, Nicholas Petrovitch, Kyle G. MathewsAbstract:Cribriform lysis has been considered a contraindication for Topical Treatment of sinonasal aspergillosis (SNA) because of concerns about drug extravasation with resultant neurologic signs or death. To describe dogs with SNA and cribriform plate lysis treated with Topical antifungal medications. Our hypothesis was that the conventional dogma that Topical therapy should be avoided in these cases is incorrect. Nine client-owned dogs with SNA and lysis of the cribriform plate, lysis of the floor of a frontal sinus or both detected by computed tomography (CT). A retrospective review of medical records was performed. Dogs that met inclusion criteria (ie, SNA confirmed by at least 1 laboratory test, braincase affected on CT, and Topical Treatment applied) were included. Size of lesions, ancillary diagnostic test results, Topical therapy, and adjuvant PO Treatments were recorded. Outcome was determined by phone calls. Four dogs were alive at the time of the manuscript submission with follow-up ranging from 188 to 684 days without neurological signs observed. All dogs were discharged without major complication 1-7 days postoperatively. One dog that had presented with a history of seizures experienced seizure activity 2 months after Treatment. Topical therapy did not result in complications in these dogs in which lytic regions as large as 16 × 22 mm2 were noted. Sinonasal aspergillosis associated lysis of the cribriform plate; lysis of the floor of a frontal sinus or both detected on CT is not necessarily a contraindication to Topical therapy. Copyright © 2018 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.
Beatriz Belda - One of the best experts on this subject based on the ideXlab platform.
-
Sinonasal aspergillosis: Outcome after Topical Treatment in dogs with cribriform plate lysis.
Journal of Veterinary Internal Medicine, 2018Co-Authors: Beatriz Belda, Nicholas Petrovitch, Kyle G. MathewsAbstract:BACKGROUND Cribriform lysis has been considered a contraindication for Topical Treatment of sinonasal aspergillosis (SNA) because of concerns about drug extravasation with resultant neurologic signs or death. OBJECTIVE/HYPOTHESIS To describe dogs with SNA and cribriform plate lysis treated with Topical antifungal medications. Our hypothesis was that the conventional dogma that Topical therapy should be avoided in these cases is incorrect. ANIMALS Nine client-owned dogs with SNA and lysis of the cribriform plate, lysis of the floor of a frontal sinus or both detected by computed tomography (CT). METHODS A retrospective review of medical records was performed. Dogs that met inclusion criteria (ie, SNA confirmed by at least 1 laboratory test, braincase affected on CT, and Topical Treatment applied) were included. Size of lesions, ancillary diagnostic test results, Topical therapy, and adjuvant PO Treatments were recorded. Outcome was determined by phone calls. RESULTS Four dogs were alive at the time of the manuscript submission with follow-up ranging from 188 to 684 days without neurological signs observed. All dogs were discharged without major complication 1-7 days postoperatively. One dog that had presented with a history of seizures experienced seizure activity 2 months after Treatment. CONCLUSIONS AND CLINICAL IMPORTANCE Topical therapy did not result in complications in these dogs in which lytic regions as large as 16 × 22 mm2 were noted. Sinonasal aspergillosis associated lysis of the cribriform plate; lysis of the floor of a frontal sinus or both detected on CT is not necessarily a contraindication to Topical therapy.
-
Sinonasal aspergillosis: Outcome after Topical Treatment in dogs with cribriform plate lysis.
Journal of veterinary internal medicine, 2018Co-Authors: Beatriz Belda, Nicholas Petrovitch, Kyle G. MathewsAbstract:Cribriform lysis has been considered a contraindication for Topical Treatment of sinonasal aspergillosis (SNA) because of concerns about drug extravasation with resultant neurologic signs or death. To describe dogs with SNA and cribriform plate lysis treated with Topical antifungal medications. Our hypothesis was that the conventional dogma that Topical therapy should be avoided in these cases is incorrect. Nine client-owned dogs with SNA and lysis of the cribriform plate, lysis of the floor of a frontal sinus or both detected by computed tomography (CT). A retrospective review of medical records was performed. Dogs that met inclusion criteria (ie, SNA confirmed by at least 1 laboratory test, braincase affected on CT, and Topical Treatment applied) were included. Size of lesions, ancillary diagnostic test results, Topical therapy, and adjuvant PO Treatments were recorded. Outcome was determined by phone calls. Four dogs were alive at the time of the manuscript submission with follow-up ranging from 188 to 684 days without neurological signs observed. All dogs were discharged without major complication 1-7 days postoperatively. One dog that had presented with a history of seizures experienced seizure activity 2 months after Treatment. Topical therapy did not result in complications in these dogs in which lytic regions as large as 16 × 22 mm2 were noted. Sinonasal aspergillosis associated lysis of the cribriform plate; lysis of the floor of a frontal sinus or both detected on CT is not necessarily a contraindication to Topical therapy. Copyright © 2018 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.
Nicholas Petrovitch - One of the best experts on this subject based on the ideXlab platform.
-
Sinonasal aspergillosis: Outcome after Topical Treatment in dogs with cribriform plate lysis.
Journal of Veterinary Internal Medicine, 2018Co-Authors: Beatriz Belda, Nicholas Petrovitch, Kyle G. MathewsAbstract:BACKGROUND Cribriform lysis has been considered a contraindication for Topical Treatment of sinonasal aspergillosis (SNA) because of concerns about drug extravasation with resultant neurologic signs or death. OBJECTIVE/HYPOTHESIS To describe dogs with SNA and cribriform plate lysis treated with Topical antifungal medications. Our hypothesis was that the conventional dogma that Topical therapy should be avoided in these cases is incorrect. ANIMALS Nine client-owned dogs with SNA and lysis of the cribriform plate, lysis of the floor of a frontal sinus or both detected by computed tomography (CT). METHODS A retrospective review of medical records was performed. Dogs that met inclusion criteria (ie, SNA confirmed by at least 1 laboratory test, braincase affected on CT, and Topical Treatment applied) were included. Size of lesions, ancillary diagnostic test results, Topical therapy, and adjuvant PO Treatments were recorded. Outcome was determined by phone calls. RESULTS Four dogs were alive at the time of the manuscript submission with follow-up ranging from 188 to 684 days without neurological signs observed. All dogs were discharged without major complication 1-7 days postoperatively. One dog that had presented with a history of seizures experienced seizure activity 2 months after Treatment. CONCLUSIONS AND CLINICAL IMPORTANCE Topical therapy did not result in complications in these dogs in which lytic regions as large as 16 × 22 mm2 were noted. Sinonasal aspergillosis associated lysis of the cribriform plate; lysis of the floor of a frontal sinus or both detected on CT is not necessarily a contraindication to Topical therapy.
-
Sinonasal aspergillosis: Outcome after Topical Treatment in dogs with cribriform plate lysis.
Journal of veterinary internal medicine, 2018Co-Authors: Beatriz Belda, Nicholas Petrovitch, Kyle G. MathewsAbstract:Cribriform lysis has been considered a contraindication for Topical Treatment of sinonasal aspergillosis (SNA) because of concerns about drug extravasation with resultant neurologic signs or death. To describe dogs with SNA and cribriform plate lysis treated with Topical antifungal medications. Our hypothesis was that the conventional dogma that Topical therapy should be avoided in these cases is incorrect. Nine client-owned dogs with SNA and lysis of the cribriform plate, lysis of the floor of a frontal sinus or both detected by computed tomography (CT). A retrospective review of medical records was performed. Dogs that met inclusion criteria (ie, SNA confirmed by at least 1 laboratory test, braincase affected on CT, and Topical Treatment applied) were included. Size of lesions, ancillary diagnostic test results, Topical therapy, and adjuvant PO Treatments were recorded. Outcome was determined by phone calls. Four dogs were alive at the time of the manuscript submission with follow-up ranging from 188 to 684 days without neurological signs observed. All dogs were discharged without major complication 1-7 days postoperatively. One dog that had presented with a history of seizures experienced seizure activity 2 months after Treatment. Topical therapy did not result in complications in these dogs in which lytic regions as large as 16 × 22 mm2 were noted. Sinonasal aspergillosis associated lysis of the cribriform plate; lysis of the floor of a frontal sinus or both detected on CT is not necessarily a contraindication to Topical therapy. Copyright © 2018 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.
Kristian Reich - One of the best experts on this subject based on the ideXlab platform.
-
Development of an adherence-enhancing intervention in Topical Treatment termed the Topical Treatment optimization program (TTOP).
Archives of dermatological research, 2014Co-Authors: Kristian Reich, Ulrich Mrowietz, Eleni Karakasili, Ina ZschockeAbstract:Psoriasis is a common, disabling, chronic, relapsing, inflammatory disorder of the skin with a worldwide prevalence of 2–3 % in which adherence to Treatment is often poor. The majority of individuals have limited disease that is being treated with Topical medication according to existing guidelines. Adherence rates are lower for Topical compared with systemic Treatment. Low medication adherence is a major problem for patients with chronic disorders as it results in suboptimal Treatment outcomes, increased risk for development of concomitant diseases, inefficient use of health resources and considerable losses to society. However, to date no adherence-enhancing intervention has been developed for psoriasis patients under Topical Treatment. In this article, we report the development of the Topical Treatment optimization program (TTOP). The TTOP intervention aims to improve the information given to the patients and to result in an engaged patient–physician relationship. Application of the TTOP intervention in daily clinical practice may lead to a significant increase of adherence and the successful management of psoriasis and other chronic skin disorders.
-
Assessing adherence factors in patients under Topical Treatment: development of the Topical Therapy Adherence Questionnaire (TTAQ)
Archives of dermatological research, 2014Co-Authors: I. Zschocke, Eleni Karakasili, Ulrich Mrowietz, Annett Lotzin, Kristian ReichAbstract:Medication adherence rates strongly depend on favorable disease outcomes. It is known that medication adherence rates are lower for Topical Treatment than for systemic Treatment. However, to date no validated instrument for the assessment of adherence factors in Topical Treatment is available. The aim of this study was to develop a new questionnaire to assess adherence risk factors in Topical Treatment. The development of the Topical Therapy Adherence Questionnaire (TTAQ) and Patient Preference Questionnaire (PPQ) was based on a systematic literature review, and qualitative patient focus interviews and expert focus groups’ input. The psychometric properties and comprehensibility of the TTAQ and PPQ were assessed in a feasibility study with 59 psoriasis patients. Our first preliminary results indicate that the TTAQ and PPQ are psychometrically sound and reliable measures for the assessment of factors influencing Topical Treatment adherence. The questionnaires are currently being further developed and various parameters (e.g., time point of assessment) are currently being tested in an exploratory pilot study with ca. 2,000 psoriasis patients receiving Topical Treatment in a European clinical trial. The use of the final versions of TTAQ and PPQ in clinical practice may facilitate the early identification of specific non-adherence factors in patients under Topical Treatment, which could enable designing and applying adherence-enhancing interventions according to the patient’s individual needs.
T. A. Luger - One of the best experts on this subject based on the ideXlab platform.
-
Successful Topical Treatment of focal epithelial hyperplasia (Heck’s disease) with interferon‐β
The British journal of dermatology, 2001Co-Authors: Martin Steinhoff, Dieter Metze, E. Stockfleth, T. A. LugerAbstract:We report the successful Topical Treatment of focal epithelial hyperplasia (Heck’s disease) with interferon-β (Fiblaferon gel®). Topical Treatment with interferon-β appears to be an effective, simple, non-invasive, cheap and low-risk alternative to other invasive or surgical therapeutic modalities.